Encapsulation of cisplatin in long-circulating and pH-sensitive liposomes improves its antitumor effect and reduces acute toxicity

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 5259-5269

  Leite, Elaine A ^a,b   Souza, Cristina M ^a   Carvalho Júnior Jr , Álvaro D ^a,b   Coelho, Luiz G V ^a   Lana, Ângela M Q ^a   Cassali, Geovanni D ^a   Oliveira, Mônica Cristina ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSIDADE FEDERAL DOS VALES DO JEQUITINHONHA E MUCURI   (Brazil)

Author keywords

Angiogenesis; Antitumor effect; Ehrlich tumor; Toxicity

Indexed keywords

CISPLATIN; LIPOSOME; VASCULOTROPIN;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; DRUG RESPONSE; EHRLICH ASCITES TUMOR; ENCAPSULATION; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MORPHOMETRICS; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN BLOOD LEVEL; TOXICITY TESTING; TUMOR VOLUME; WEIGHT CHANGE; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, EHRLICH TUMOR; CISPLATIN; DELAYED-ACTION PREPARATIONS; FEMALE; HYDROGEN-ION CONCENTRATION; LIPOSOMES; MICE; NANOCAPSULES; TREATMENT OUTCOME;

MUS;

EID: 84870362208     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S34652     Document Type: Article

References (22)

1. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33(1): 9-23.
2. Wang LR, Liu J, Huang MZ, Xu N. Comparison of pharmacokinetics, efficacy and toxicity profile of gemcitabine using two different administration regimens in Chinese patients with non-small-cell lung cancer. J Zhejiang Univ Sci B. 2007;8(5):307-313.
3. Carvalho Júnior AD, Vieira FP, Melo VJ, etal. Preparation and cytotoxicity of cisplatin-containing liposomes. Braz J Med Biol Res. 2007;40(8): 1149-1157.
4. Júnior AD, Mota LG, Nunan EA, etal. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice. Life Sci. 2007;80(7):659-664.
5. Allen TM, Newman MS, Woodle MC, Mayhew E, Uster PS. Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int J Cancer. 1995;62(2):199-204.
6. Uchino H, Matsumura Y, Negishi T, etal. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer. 2005;93(6):678-687.
7. Leite EA, Giuberti CS, Wainstein AJ, etal. Acute toxicity of long-circulating and pH-sensitive liposomes containing cisplatin in mice after intraperitoneal administration. Life Sci. 2009;84(19-20):641-649.
8. Leite EA, Lana AM, Junior AD, Coelho LG, De Oliveira MC. Acute toxicity study of cisplatin loaded long-circulating and pH-sensitive liposomes administered in mice. J Biomed Nanotechnol. 2012;8(2):229-239.
9. De Oliveira MC, Fattal E, Couvreur P, etal. pH-sensitive liposomes as a carrier for oligonucleotides: a physico-chemical study of the interaction between DOPE and a 15-mer oligonucleotide in quasi-anhydrous samples. Biochim Biophys Acta. 1998;1372(2):301-310.
10. Zamboni WC, Jung LL, Egorin MJ, etal. Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors. Clin Cancer Res. 2004;10(15):5058-5064.
11. Lee CM, Tanaka T, Murai T, etal. Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res. 2002; 62(15):4282-4288.
12. Hoving S, van Tiel ST, Eggermont AM, ten Hagen TL. Effect of low-dose tumor necrosis factor-alpha in combination with STEALTH liposomal cisplatin (SPI-077) on soft-tissue-and osteosarcoma-bearing rats. Anticancer Res. 2005;25(2A):743-750.
13. Araújo JG, Mota LG, Leite EA, etal. Biodistribution and antitumoral effect of long-circulating and pH-sensitive liposomal cisplatin administered in Ehrlich tumor-bearing mice. Exp Biol Med (Maywood). 2011; 236(7):808-815.
14. Gryparis EC, Hatziapostolou M, Papadimitriou E, Avgoustakis K. Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur J Pharm Biopharm. 2007;67(1): 1-8.
15. Kurihara N, Kubota T, Hoshiya Y, etal. Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions. J Surg Oncol. 1996;62(2):135-138.
16. Vassileva V, Grant J, De Souza R, Allen C, Piquette-Miller M. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model. Cancer Chemother Pharmacol. 2007;60(6):907-914.
17. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 2002;29(6 Suppl 16):S10-S14.
18. Moreno D, Zalba S, Navarro I, Tros de Ilarduya C, Garrido MJ. Pharmacodynamics of cisplatin-loaded PLGA nanoparticles administered to tumor-bearing mice. Eur J Pharm Biopharm. 2010;74(2): 265-274.
19. Suddek GM. Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals. Cancer Chemother Pharmacol. 2011;67(5):1035-1044.
20. Working PK, Newman MS, Sullivan T, etal. Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys. Toxicol Sci. 1998;46(1):155-165.
21. Asna N, Lewy H, Ashkenazi IE, etal. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity. Life Sci. 2005;76(16):1825-1834.
22. Boulikas T. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep. 2004;12(1): 3-12.